XGN: Roth Initiates Buy
Roth Capital initiates coverage on Exagen with a Buy rating and $8 price target
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ: XGN ) with a Buy rating and announces Price Target of $8.
Roth Capital initiates coverage on Exagen with a Buy rating and $8 price target
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ: XGN ) with a Buy rating and announces Price Target of $8.